Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...
The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...
Emgality (galcanezumab-gnlm) and Ajovy (fremanezumab-vfrm) are prescription drugs that help prevent migraine episodes. Both drugs come as a liquid solution that you inject under the skin. Emgality and ...
Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly ...
TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for Pr AJOVY® (fremanezumab solution for subcutaneous injection) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results